Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Tumor markers like CEA and CYFRA21-1 can help distinguish between ALK-positive and EGFR-positive lung cancers. Higher CYFRA21-1:CEA ratios were observed in ALK-positive cases, aiding in predicting gene mutations.
Area Of Science
- Oncology
- Molecular Diagnostics
- Biomarker Research
Background
- Predicting specific gene mutations in lung cancer based solely on clinical factors is challenging.
- Tumor markers show potential in predicting gene mutations, facilitating earlier genetic testing and treatment.
- Identifying reliable tumor markers is crucial for timely intervention in lung cancer patients.
Purpose Of The Study
- To investigate the utility of tumor markers, specifically carcinoembryonic antigen (CEA) and soluble fragment of cytokeratin 19 (CYFRA21-1), in differentiating between ALK-positive and EGFR-positive advanced or recurrent lung cancers.
- To determine if the ratio of CYFRA21-1 to CEA can serve as a predictive marker for specific genetic mutations in lung cancer.
Main Methods
- Retrospective analysis of 134 ALK-positive and 172 EGFR-positive advanced/recurrent lung cancer cases.
- Defined cutoff values: CEA ≥ 5.0 ng/mL, CYFRA21-1 ≥ 3.5 ng/mL.
- Established a positive CYFRA21-1:CEA ratio as ≥ 0.7.
Main Results
- Significantly higher CEA positivity in EGFR-positive (73%) vs. ALK-positive (49%) lung cancer (p < 0.001).
- Significantly higher CYFRA21-1 positivity in ALK-positive (36%) vs. EGFR-positive (23%) lung cancer (p = 0.034).
- Median CYFRA21-1:CEA ratio was significantly higher in ALK-positive (0.395) compared to EGFR-positive (0.098) lung cancer (p < 0.001).
Conclusions
- ALK-positive lung cancer patients exhibit a higher proportion of CYFRA21-1 positivity and elevated CYFRA21-1:CEA ratios compared to EGFR-positive patients.
- These findings suggest that CYFRA21-1 and its ratio with CEA can be valuable biomarkers for distinguishing between ALK and EGFR mutations in lung cancer.
- This distinction can potentially guide genetic testing and therapeutic strategies in advanced lung cancer.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...